Effects of Vitamin K2 and D Supplementation on Coronary Artery Disease in Men: A RCT
Authors' conclusion
Patients with no prior ischemic heart disease randomized to vitamin K2 and D supplementation had no significant reduction in mean CAC progression over a 2-year follow-up compared to placebo.
Study context
- Population
- Men with no ischemic heart disease (mean age 71 years)389 randomised
- Participants
- 304 men
- Comparison
- Vitamin K2 and D supplementation vs placebo
- Primary endpoint
- Progression of aortic valve calcification (trial primary endpoint, reported previously; this report: CAC progression)
Methodological detailsmulticentre, double-blind, placebo-controlled, Trial primary endpoint (aortic valve calcification progression) reported elsewhere
- Multicentre
- Double-blind
- Placebo-controlled
- Trial primary endpoint (aortic valve calcification progression) reported elsewhere
Primary result
As reported in the abstract
Mean CAC score change · 24 months
Intervention
203
mean change · AU
Placebo
254
mean change · AU
P = 0.089
Further findings
Coronary artery calcification (CAC) progression in CAC score ≥400 AU (subgroup) · 24 months
- CAC progression lower with intervention vs placebo (ΔCAC)
- Δ288 vs Δ380 AU, P = 0.047
Progression of noncalcified plaque volume
- No significant difference in progression of noncalcified plaque volume
- Δ-6 vs Δ46 mm³, P = 0.172
Safety
Safety endpoint: composite of MI, coronary revascularization and all-cause mortality
- Safety events fewer with supplementation vs placebo
- 1.9% vs 6.7%, P = 0.048
Original publication
Effects of Vitamin K2 and D Supplementation on Coronary Artery Disease in Men: A RCT. JACC Adv. Published 24 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →